Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2015—The Methotrexate ELISA kit from Enzo Life Sciences enables the monitoring of methotrexate levels during treatment of cancer and rheumatoid arthritis. The assay is also appropriate for the detection of methotrexate contamination after its use as a selective agent for recombinant protein production in mammalian cell lines.
May 2015—Sarstedt is offering two urine collection systems—the Urine Monovette and the V-Monovette. The Urine Monovette enables hygienic urine collection and testing without needles, adapters, or cups or transfers. All tubes are manufactured from impact-resistance, medical-grade plastics and feature secure screw caps for safe handling. After collection using a syringe technique, the plunger handle is removed to create a primary tube for transport, direct analysis, and centrifugation. A Luer-lock version is also available for needleless collection from Foley catheters.
May 2015—Bio-Rad announced the launch of the BioPlex 2200 25-OH Vitamin D kit for use on the company’s BioPlex 2200 system in U.S. markets. The assay offers a fully automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum.
May 2015—Radiometer has announced the launch of a dedicated Individualized Quality Control Plan tool for hospitals using the ABL90 Flex blood gas analyzer. The IQCP tool provides a template for hospitals with ABL90 Flex analyzers to develop a customized quality control plan. Starting at the preanalytical phase, the tool next guides the laboratorian through the analytical and postanalytical processes, identifying key areas of focus to ensure the development of an IQCP program that is right for each institution.
May 2015—The Digital Pathology Association is commending the FDA for developing and releasing draft guidance that provides industry and agency staff with recommendations regarding the technical performance assessment data that should be submitted for regulatory evaluation of a digital whole-slide imaging system.
April 2015—Qiagen has expanded its portfolio of liquid biopsies through the acquisition of a proprietary technology from AdnaGen. The technology allows a complete solution for the detection and analysis of circulating tumor cells for clinical applications. It enriches disease-specific tumor cells using magnetic particles in an antibody mixture, then isolates and purifies messenger RNA for analysis using reverse transcription polymerase chain reaction.
April 2015—Eppendorf and the journal Science are accepting applications for the 2015 Eppendorf & Science Prize for Neurobiology.
April 2015—Agena Bioscience released the MassArray 24-Well System for mass spectrometry-based genetic analysis. The 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result.
April 2015—Agendia received 510(k) clearance from the Food and Drug Administration for its MammaPrint breast cancer recurrence test in formalin-fixed, paraffin-embedded tissue.
April 2015—The diagnostics division of Siemens Healthcare has announced the U.S. availability of its Advia Centaur Syphilis assay to be used as a diagnostic aid. The assay, which allows for sensitive and specific detection of antibodies to the proteins of Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate), is available on the company’s Advia Centaur, Centaur XP, and Centaur CP immunoassay systems. It is not intended for blood and tissue donor screening.
